Lappe Mark
CIK 0001366074
Chief Executive OfficerDirector
Filings
9
Latest Sep 16, 2024
Issuers covered
2
Showing
9 of 9
Page 1
Track record
11 of 15 open-market trades scored (73% price coverage) - 4 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 11 | 73% | +6.3% | +2.8% | +35.5% | -7.9% |
| 90 days | 11 | 55% | +0.2% | +0.3% | +12.4% | -16.5% |
| 180 days | 11 | 18% | -10.8% | -13.5% | +1.2% | -20.0% |
| 365 days | 11 | 100% | +83.7% | +85.1% | +102.7% | +52.4% |
Issuers
Companies where Lappe Mark has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc. | 5 | Sep 16, 2024 |
| INBX | Inhibrx, Inc. | 4 | May 30, 2024 |
All filings
9 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|